“The data presented at SOHO this year highlight the outcomes from the Phase 3 DUO study in the labeled indication, as well as supplemental lymphocytosis data, and continue to support its ongoing use in patients with relapsed or refractory CLL/SLL,” said Hagop Youssoufian, MSc, M.D., Head of Medical Strategy at Verastem Oncology. “These findings not only support the ongoing use of duvelisib in its labeled indication for patients with relapsed or refractory CLL/SLL, but they also suggest that therapy with duvelisib may offer promise warranting further investigation in patients with refractory MZL, for whom limited treatment options exist.”
Bullish Wedge Pattern here, I've added more shares here between $1.19 and $1.24 in the last two days. Calm before the storm, Verastem is poised to move, that's why I'm buying the stock here now, not the options.
Long term hold for me now. I still believe they are buyout candidate.